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Background: In acute myeloid leukemia (AML), the MDS1 and EVI1 complex locus - MECOM, also known as the
ecotropic virus integration site 1 - EVI1, located in band 3q26, can be rearranged with a variety of partner chromosomes
and partner genes. Here we report on a 57-year-old female with AML who presented with the rare translocation t(3;10)
(q26;q21) involving the MECOM gene. Our aim was to identify the fusion partner on chromosome 10q21 and to
characterize the precise nucleotide sequence of the chromosomal breakpoint.
Methods: Cytogenetic and molecular-cytogenetic techniques, chromosome microdissection, next generation
sequencing, long-range PCR and direct Sanger sequencing were used to map the chromosomal translocation.
Results: Using a combination of cytogenetic and molecular approaches, we mapped the t(3;10)(q26;q21) to the single
nucleotide level, revealing a fusion of the MECOM gene (3q26.2) and C10orf107 (10q21.2).
Conclusions: The approach described here opens up new possibilities in characterizing acquired as well as congenital
chromosomal aberrations. In addition, DNA sequences of chromosomal breakpoints may be a useful tool for unique
molecular minimal residual disease target identification in acute leukemia patients.
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EVI1 is one of several protein isoforms encoded by the
MECOM locus at human chromosome 3q26 that also
yields the MDS1 and MDS1-EVI1 protein isoform [1].
The role of MDS1 and MDS1-EVI1 in malignancy is still
unclear, though the EVI1 transcription factor plays an
essential role in the proliferation and maintenance of
hematopoietic stem cells [2]. Aberrant EVI1 expression
occurs in approximately 8% of patients with de novo
acute myeloid leukemia (AML) [3]. The overexpression of
EVI1 can be achieved not only through rearrangements of
band 3q26 but also without the presence of 3q26 abnor-
malities, therefore indicating that other mechanisms can
lead to EVI1 activation [4-6]. Moreover, a substantial
number of patients with 3q26 rearrangements do not* Correspondence: tereza.jancuskova@synlab.cz
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article, unless otherwise stated.express EVI1 [7]. In approximately 2% of AML cases,
inv(3)(q21q26)/t(3;3)(q21;q26) is observed, where it has
been suggested that the promoter of the house-keeping
RPN1 gene could be responsible for the activation of EVI1
[8]. Other EVI1 rearrangements include, e.g. 7q21
(CDK6), 7q34 (TCRB), 12p13 (ETV6) and 21q22 (RUNX1)
[6,9]. Even though partner chromosomes and molecular
consequences differ between various types of EVI1 rear-
rangements, elevated expression predicts poor prognosis
for the affected patients [4,10,11].
Here we report the rare case of chromosomal trans-
location t(3;10)(q26;q21) involving MECOM. Using
modern cytogenetic and molecular biological techniques
we were able to characterize the nucleotide sequence of
this breakpoint and thus identify the fusion partner on
chromosome 10.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 2 FISH analysis. Metaphase-FISH analysis using EVI1 break-apart
probe shows normal fusion signal on chromosome 3 (green, purple,
blue) and split-signal on der(3) (green, blue) and der(10) (green, purple)
indicating rearrangements of 3q26 region.
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A 57-year old female was diagnosed with AML (FAB M2)
after a blood cell count and bone marrow examination
was initiated in June 2013. Hematologic parameters were
as follows: hemoglobin 6,2 g/dl, platelets 44 × 109/l,
and white blood cells (WBC) 3,34 × 109/l with 7,8%
neutrophils, 62,9% lymphocytes and 28,7% monocytes,
0% eosinophils and 0,3% basophils. A bone marrow
aspirate revealed slightly hypercellular marrow with normo-
cellular particles. Megakaryocytes were found in reduced
density. There was significant hiatus leucaemicus with
evidence of medium-sized blasts with poor basophilic
cytoplasm and distinct granulation. Flow cytometry
performed on the bone marrow revealed 31% myeloid-
appearing blasts with expression of CD34 and CD117,
and confirmed the diagnosis of AML.
Conventional cytogenetic analysis of a 24-h culture,
performed on bone marrow cells by standard techniques
and evaluated by G-banding, revealed a balanced t(3;10)
(q26;q21) in 20/22 metaphases. Involvement of the
MECOM gene was confirmed by FISH with the use of
a commercially available probe set.Results
Cytogenetic and molecular-cytogenetic analyses of bone
marrow cultures revealed an aberrant karyotype 46,XX,t
(3;10)(q26;q21) – Figure 1. A commercial EVI1 break-apart
probe yielded a split signal in all dividing and 80% of the
interphase bone marrow cells, demonstrating the re-
arrangement of the 3q26 chromosomal region (Figure 2).
Ten derivative chromosome 10 breakpoint regions
were dissected, amplified and sequenced. In total, 81 753
reads were obtained and aligned to reference sequences of
chromosomes 3 and 10 (NCBI build 37.3). Long-rangeFigure 1 Karyotype analyses. G-banding (left part) and multicolor FISH (m
(q26;q21). The arrows indicate the derivative chromosomes.PCR primer design resulted in a product that was then
subjected to Sanger sequencing. The nucleotide sequence
of the der(10) breakpoint (Figure 3) revealed a fusion of
theMECOM gene on 3q26 to C10orf107 on 10q21.
Additionally, the bone marrow sample was subjected
to reverse transcription real-time PCR analysis to deter-
mine the expression levels of cEVI1 (i.e., the sum of all
EVI1 mRNA variants) relative to those of the internal
reference gene ABL. We found that EVI1 expression was
26-fold higher when compared with healthy control (data
not shown).Discussion
In the present report we describe a rare case of acute
myeloid leukemia with a t(3;10)(q26;q21) translocation
involving MECOM. To our knowledge [12], only one case
with this translocation has been reported [9], but the fu-
sion partner on chromosome 10 was not characterized.
Using a novel technical approach we were able to identify
the fusion partner and precise nucleotide sequence of the
breakpoint, which may serve as a patient-specific molecu-
lar target for subsequent real-time PCR-based minimalFISH) (right part) analyses showed aberrant karyotype 46,XX,t(3;10)
Figure 3 Derivative chromosome 10 breakpoint sequence. The
electropherogram shows the result of direct sequencing of
long-range PCR product which revealed fusion of MECOM gene
on chromosome 3q26.2 and C10orf107 on chromosome 10q21.2.
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strated by real-time quantitative reverse transcription PCR
that the t(3;10)(q26;q21) results in EVI1 over-expression.
Deregulated expression of EVI1 and other genes (e.g.
BAALC, WT1) involved in cell proliferation, survival and
differentiation have been used as alternative MRD targets
[13-16]. However, the sensitivity of expression assays is
dependent on the level of initial expression; therefore,
these assays are suitable only in AML cases with a high
initial expression level of a specific target normalized to
an endogenous control gene at diagnosis. Even in those
cases, the sensitivity is usually not sufficient for subse-
quent MRD monitoring. Therefore, in patients presenting
with a fusion transcript and/or gene mutation, a specific
PCR assay is preferred. These PCR-based methods are
currently the most sensitive techniques for MRD follow-
up, reaching sensitivities of 10−4 – 10−5 [17,18].
Real-time PCR-based MRD assays allow the highly
accurate quantification of residual leukemic cells and
evaluations of treatment outcome in AML patients. The
merit of MRD monitoring during patient‘s treatment and
prognostic relevance has been confirmed by various studies
[17,19,20]. Common targets for MRD detection include
fusion transcripts (e.g. RUNX1-RUNX1T1, PML-RARα,
DEK-NUP214, CBFβ-MYH11) [21] and mutations of clin-
ically relevant genes (e.g. NPM1, CEBPα, FLT3, c-KIT)
[17-22]. Unfortunately, approximately half of AML pa-
tients lack a molecular target suitable for MRD moni-
toring [23]. Therefore, introducing novel approaches
for the identification of unique clone-specific markers
is highly desirable. The procedure described here is
based on characterizing nucleotide sequences of unique
chromosomal breakpoints, allowing the design of a spe-
cific real-time PCR assay for MRD assessment. In this
way, AML patients could benefit from accurate and sensi-
tive MRD monitoring, even in the absence of other well-
introduced molecular marker [24].
Mapping chromosome breakpoints is a conventional
method for identifying specific genes in leukemic patients,
as well as patients with solid tumors and individuals with
balanced translocations [25-27]. A fundamental require-
ment is the ability to karyotype and precisely identifyderivative chromosomes using classic karyotyping or mo-
lecular cytogenetic tools such as mFISH and mBAND
analyses. Hybridization with even higher resolution, such
as BAC-FISH (Bacterial Artificial Chromosome FISH)
can help to narrow-down the chromosomal breakpoints
further, though it is still not subtle enough to allow sub-
sequent molecular methods to be used and to identify
nucleotide sequence. There have been a number of
methods proposed to address this issue, with varying
strengths and weaknesses. Array-CGH has improved in
resolution, allowing deletions, amplifications, and non-
balanced translocations to be more precisely character-
ized, but array-CGH in principle cannot detect targets
arising from balanced chromosomal translocations [28].
Conclusion
The combination of cytogenetic and molecular methods
described here enabled us to proceed from the chromo-
somal level (cytogenetically identified abnormality) to the
molecular level (unique DNA sequence) in a case of the
novel t(3;10)(q26;q21) translocation. Using this procedure,
acquired as well as congenital chromosomal aberrations
can be characterized. In contrast to other mapping
methods (e.g. BAC-FISH, array CGH) our technique
allows the rapid mapping of chromosomal breakpoints
down to the DNA sequence level and immediate elucida-
tion of possible genes involved. This can be invaluable for
studying such aberrations in a wide variety of fields,
including the evolution of diseases or the genetic basis of
inherited syndromes.
Methods
Cytogenetic and molecular cytogenetic analyses
The heparinized bone marrow sample was cultivated for
24 h in RPMI 1640 media supplemented with 10% fetal
calf serum, penicillin/streptomycin and L-glutamine (PAA
Laboratories, Austria) at 37°C/5% CO2. Karyotype was
investigated by G-banding and multiplex fluorescence in
situ hybridization (mFISH) with the 24XCyte probe kit
(MetaSystems, Germany). ISCN 2013 nomenclature
was used to describe chromosome abnormalities [29].
Interphase fluorescence in situ hybridization (FISH)
analysis was performed using a commercially available
EVI1 break-apart probe (MetaSystems, Germany).
DNA/RNA isolation, reverse transcription
DNA and RNA were isolated from the mononuclear frac-
tion of bone marrow samples at diagnosis. DNA was iso-
lated using the MagNA Pure automatic isolator (Roche,
Germany) according to the manufacturer’s instructions.
RNA was extracted by TRI Reagent (Molecular Research
Center, USA) according to the manufacturer’s recommen-
dations. Reverse transcription was performed using the
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according to the manufacturer’s instructions.
Real-time quantitative reverse transcriptase PCR
Primers and probes to amplify and quantify EVI1-
expression were forward: 5′ ACCCACTCCTTTCTTTA
TGGACC 3′, reverse: 5′ TGATCAGGCAGTTGGAATT
GTG 3′, probe: FAM - 5′ TGAGGCCTTCTCCAGGAT
TCTTGTTTCAC 3′ - BHQ1. Expression was normalized
against the expression of the control gene ABL. Primers
and probe to quantify ABL gene were as follows: forward:
5′ TCCTCCAGCTGTTATCTGGAAGA 3′, reverse: 5′ T
GGGTCCAGCGAGAAGGTT 3′, probe: FAM-5′ CCAG
TAGCATCTGACTTTGAGCCTCAGGG 3′ - BHQ1.
PCR conditions started with a denaturation at 95°C for
8 minutes, followed by 45 cycles of denaturation at 95°C
for 20 s, annealing at 57°C for 30 s and elongation at 72°C
for 30 s.
Chromosomal breakpoint identification
The cell suspension and DNA sample were treated and
analyzed as previously described [24]. Briefly, regions
around the breakpoints of derivative chromosomes
were dissected by glass microneedles manipulated by
micromanipulator using an inverted microscope (Axiovert
10, Zeiss, Germany). The microdissected fragments were
directly subjected to amplification by degenerate oligo-
nucleotide-primed (DOP) PCR and then sequenced on
the GS Junior platform (Roche, Germany) for next gener-
ation sequencing. Obtained reads were aligned to refer-
ence sequences of chromosomes 3 and 10, using in-house
developed software. The last mapped reads from both
chromosomes were used as docking sites for primers for
long-range PCR to amplify the putative breakpoint.
Primers for long-range PCR were designed in Vector
NTI Advance (v. 11.5, Invitrogen, USA). PCR amplifica-
tion was done using the Expand Long Range dNTPack
kit (Roche, Germany). The long-range PCR product was
directly sequenced using Sanger sequencing to reveal
the precise nucleotide sequence of the breakpoint.
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